Neumora Stock Falls 26% as Firm Launches Fraud Investigation

Edgen Stock·Mar 20 2026, 00:06

Share to

Share to

Copy link

Key Takeaways

Neumora Therapeutics (NMRA) is facing a securities fraud investigation from The Schall Law Firm, compounding pressure on the stock which has fallen significantly in March. The probe, announced March 19, 2026, alleges violations of securities laws and invites investor participation, creating legal and reputational risks for the clinical-stage biopharmaceutical company ahead of its earnings report.

Legal Scrutiny: The Schall Law Firm announced it is investigating Neumora Therapeutics for potential securities law violations.
Stock Performance: NMRA shares closed at $2.57 on March 19, contributing to a 26.36% decline so far in March.
Upcoming Catalyst: The investigation comes just before Neumora is scheduled to report its full-year 2025 financial results on March 30, 2026.

Law Firm Launches Fraud Probe into Neumora

The Schall Law Firm announced on March 19, 2026, that it is investigating Neumora Therapeutics, Inc. (NMRA) for alleged violations of securities laws. The national shareholder rights firm is examining whether the company issued false or misleading statements and failed to disclose critical information to investors. The investigation invites shareholders who have suffered losses to contact the firm, signaling a potential move toward a class-action lawsuit which could expose Neumora to significant legal costs and reputational damage.

NMRA Stock Declines 26.36% in March

Neumora's stock has faced substantial selling pressure, exacerbating investor concerns. On March 19, the day of the investigation's announcement, NMRA shares closed at $2.57, a 2.65% drop from the previous session. The decline is part of a broader negative trend, with the stock falling 26.36% month-to-date in March. This performance has pushed the stock price toward its monthly low of $2.51, erasing a significant portion of its prior gains.

Earnings Call on March 30 Faces Heightened Scrutiny

This legal challenge arrives at a critical time for Neumora. The company is scheduled to host a conference call on March 30, 2026, to report its fourth-quarter and full-year 2025 financial results. With the fraud investigation now public, investors and analysts will be intensely scrutinizing management's business updates and financial disclosures. The call will be a key event for the company to address the allegations and restore market confidence.